Antihyperalgesic and antiallodynic effects of mianserin on diabetic neuropathic pain: A study on mechanism of action

Üçel, Umut İrfan; Can, Özgür Devrim; Özkay, Ümide Demir; Öztürk, Yusuf

doi:10.1016/j.ejphar.2015.02.048

Cited by 18 publications

(41 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same volume of citrate buffer was injected intravenously (i.v.) to healthy rats, which were used as controls .…”

Section: Methodsmentioning

confidence: 99%

“…Treatments were started 4 weeks after the induction of diabetes to permit the development of peripheral neuropathy in diabetic rats .…”

Section: Methodsmentioning

confidence: 99%

“…for 14 days), PCPA (300 mg/kg i.p . daily for 2 days) was administrated 30 minutes before receiving the last dose of agomelatine AMPT studies: Vehicle + DM group Following vehicle treatment (14 days, p.o . ), physiological saline was administrated ( i.p .)…”

Section: Methodsmentioning

confidence: 99%

“…Diabetic neuropathy (DN), one of the most common chronic complications in patients with long‐standing diabetes, is a syndrome that develops solely in DM, regardless of other factors. It affects various components of the nervous system and can damage all types of nerve fibers . Peripheral DN resulted from damage to somatic or autonomous nerves may cause persistent neuropathic pain.…”

Section: Introductionmentioning

confidence: 99%

“…Peripheral DN resulted from damage to somatic or autonomous nerves may cause persistent neuropathic pain. As the magnitude of pain increases, patients’ daily functions become progressively disrupted and life quality decreases .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms

Aydin

Can

Özkay

et al. 2016

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

In this study, we investigated the effects of subacute agomelatine (40 and 80 mg/kg) administration on chronic hyperglycemia, metabolic parameters, and pain perception in streptozotocin-induced diabetic rats. Fasting blood glucose measurements and oral glucose tolerance tests were performed to evaluate the effect of agomelatine on glycemia, while metabolic parameters were monitored using metabolic cages. Potential effect of agomelatine on diabetes-induced mechanical and thermal allodynia was evaluated using dynamic plantar aesthesiometer and warm plate (38 °C) tests, respectively. Additionally, influence of agomelatine on hyperalgesia occurring in connection with diabetic neuropathy was examined using the Randall-Selitto (mechanical nociceptive stimulus), Hargreaves (thermal nociceptive stimulus), and cold plate (4 °C, thermal nociceptive stimulus) tests. Obtained data indicated that, in diabetic rats, agomelatine significantly improved hyperalgesia and allodynia responses, without no effect on hyperglycemia or the associated polydipsia, polyuria, and hyperphagia. Therapeutic potential of agomelatine on neuropathic pain was suppressed with α-methyl-para-tyrosine methyl ester (an inhibitor of catecholamine synthesis), phentolamine (a nonselective α-adrenoceptor antagonist), and propranolol (a nonselective β-adrenoceptor antagonist) administrations. However, p-chlorophenylalanine methyl ester (an inhibitor of serotonin synthesis) pretreatment could not be achieved to reverse these antihyperalgesic and antiallodynic effects. These results suggest that the curative effect of agomelatine on neuropathic pain is mediated through rising synaptic catecholamine levels as well as through interactions with both α- and β-adrenoceptors. To our knowledge, this is the first study to show findings that indicate catecholaminergic system mediated antihyperalgesic and antiallodynic effects of agomelatine.

show abstract

“…The same volume of citrate buffer was injected intravenously (i.v.) to healthy rats, which were used as controls .…”

Section: Methodsmentioning

confidence: 99%

“…Treatments were started 4 weeks after the induction of diabetes to permit the development of peripheral neuropathy in diabetic rats .…”

Section: Methodsmentioning

confidence: 99%